Progress in developing disease-modifying therapies in Parkinson's disease (PD) can only
be achieved through reliable objective markers that help to identify subjects at risk. This …

In Parkinson's disease (PD), there is a wide field of recent and ongoing search for useful
biomarkers for early and differential diagnosis, disease monitoring or subtype …

The development of disease modifying strategies in Parkinson's disease (PD) largely
depends on the ability to identify suitable populations after accurate diagnostic work-up …

Introduction Neurodegenerative parkinsonian syndromes have significant clinical and
pathological overlap, making early diagnosis difficult. Cerebrospinal fluid (CSF) biomarkers …

Parkinson's disease (PD) is a common neurodegenerative disorder; however, well-
established biochemical markers have not yet been identified. This review article covers …

The inaccuracy of the early diagnosis of Parkinson's disease (PD) has been a major
incentive for studies aimed at the identification of biomarkers. Brain-derived cerebrospinal …

Parkinson's disease (PD) is a prevalent neurodegenerative illness that is often diagnosed
after significant pathology and neuronal cell loss has occurred. Biomarkers of PD are greatly …

Diagnosis of Parkinson's disease (PD) relies on clinical history and physical examination,
but misdiagnosis is common in early stages. Identification of biomarkers for PD may allow …

Biomarkers for detecting the early stages of Parkinson's disease (PD) could accelerate
development of new treatments. Such biomarkers could be used to identify individuals at risk …

Parkinson's disease is a chronic neurodegenerative disorder leading to progressive motor
impairment affecting more than 1% of the over-65 population. In spite of considerable …